glp-1 drugs retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 People dropped out of retatrutide

Novo Nordisk spent approximately $6.3 billion on production investments in 2023 and increased that figure to approximately $6.8 billion in 2024

Differences were assessed using a Wilcoxon matched-pairs test

Industry experts estimate that small-molecule production costs could be 10 to 100 times lower than peptide biologics, a differential with profound implications for drug pricing, insurance coverage, global access, and the long-term sustainability of GLP-1-based obesity treatment

Campisciano G, Florian F, D'Eustacchio A, et al

Becker C, Brobert GP, Johansson S, Jick SS, Meier CR

By month 3, most patients tolerate the medication well